This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating r | Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) (..)
The challenge for pharma in reducing its carbon footprint A recent study presented at COP27 , found that just 4% of biotechnology and pharmaceutical companies were currently on track to meet Paris 2030 climate goals, with the pharmaceutical industry being among the world’s largest carbon emitters.
transportation), and indirect expenses (e.g., Pharma companies are aware that insurers will rarely say no to new cancer therapies, but increased scrutinization of early approvals is on the horizon. copayments and deductibles), nonmedical fees (e.g., lost work and income). The post The financial toxicity of treating cancer.
80% provide transportation 1. 5 While the CDC gathers information on these topics for public health planning, there are immediate needs that pharma can address. . What Can Pharma Do? Pharma can help with caregiver-relevant labeling, training to perform nursing duties, and a multitude of other support services.
Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push across cancer, immune-mediated, and neurological diseases.
The April issue of Pharmaceutical Commerce examines the accelerated activityand many ever-expanding layersof temperature-sensitive transport in pharma.
French biopharmaceutical firm Ipsen has concluded the purchase of US-based Albireo Pharma , expanding its rare disease portfolio. Albireo’s pipeline includes its lead asset, Bylvay (odevixibat), a potent, once-a-day, oral, non-systemic, ileal bile acid transport inhibitor (IBATi).
When people think about pharma, they often think about “big” pharma: large, faceless corporations. Every pharma company developing treatments for new diseases is contributing to some degree to better global health. The post How one pharma “family business” places patients first appeared first on.
In a letter to energy ministers, they stated that raw material prices have risen by as much as 50–160% and transportation costs by up to 500%. It also stresses that some pharma manufacturers are at risk of having gas rationed or being unable to continue manufacturing due to high prices.
When identifying a third-party service provider for ground transport of pharmaceutical freight, it is essential that the shipper partner with a company equipped with the expertise and technologies to plan for and monitor necessary shipments as well as respond to issues that may compromise the freight along its journey.
The North Ireland Protocol has been a source of tension between the UK and EU since it came into force at the start of 2021 – and according to one pharma company the end of the so-called ‘grace period’ could result in major issues with medicines supply.
Cold chain – a vital part of medical logistics Cold chain refers to the transportation and storage of temperature-controlled medications. The investment will enable an estimated 150 medical-grade refrigeration units to be installed at 25 Life for a Child partner facilities in Africa, Latin America, the Caribbean and Southeast Asia.
Tablets were noted to be the most common form of OSD in 2021 because of their convenience and simplicity in production, transportation and delivery to the end user. Lonza Group, Piramal Pharma Solutions, Aenova, Jubilant, Boehringer Ingelheim, AbbVie Contract Manufacturing, Patheon, Recipharm, Next Pharma AB, Siegfried AG and Corden Pharma.
Challenges in the pharmaceutical supply chain Pharmaceutical supply chain issues include long transportation distances, low transparency of inventory levels and cargo theft. These can lead to inventory shortages, the paper noted. For instance, these drugs must be equipped with real-time insights.
Clinical studies have demonstrated its potential in regulating genes involved in bile acid synthesis, inflammation, fibrosis and lipid metabolism, storage, and transport. A continued focus on treatments for liver disorders In recent months, several Big Pharma companies have made major deals centred on advancing treatments for liver diseases.
CPHI Barcelona, the renowned global pharma event, is set to take centre stage from 24 to 26 October 2023 at Fira Barcelona Gran Via, Spain. CPHI creates connections and inspires partnerships across the global pharma community. CPHI creates connections and inspires partnerships across the global pharma community.
Integrating AI into the operations of retail pharmacies helps in improving the decision-making process, order fulfilment, demand forecasting, and monitoring of the transportation and storage environment. The post Leading retail pharmacies in pharma appeared first on Pharmaceutical Technology.
Despite their infrequency, in-person advisory boards are associated with substantial travel-related greenhouse gas emissions , as well as a large environmental footprint from things like printed agendas and collateral materials, catering (including transportation) of food and drinks, accommodation, audio-visual (AV) rentals, and much more.
We pride ourselves on developing global transport solutions that mitigate risks and deliver real-time supply chain tracking and visibility. But getting these drugs to patients requires risky transportation, and safety and success hinges on reliable, temperature-controlled logistics.
In the realm of pharma, where the presentation of drug samples is as critical as the information relayed, these bags serve a pivotal role. Far from being just a means of transport, it’s a multi-faceted asset that elevates the art of salesmanship through organization, durability, security, and professional presentation.
Detail of Containment Solution (credit: IMA Pharma) Considering the pharmaceutical industry is required to comply with strict GMP standards, all our high-tech aseptic filling lines are developed in line with these guidelines. credit: IMA Pharma) A pack not only has a functional purpose of protecting, conserving and transporting the product.
Transportation facility. AUXILLA Pharma-HR. Pharm (Pharmaceutics). Experience: 0 to 01 years. Benefits: 5 days working. food facility. Mediclaim & accident insurance. 9 days Diwali Vacation etc. Candidates willing to stay committed for at least 2/3 years shall only apply for the job.
Credit: IMA Pharma – AQUARIA The Continuous Direct Compression Line (CDC Line), a very lean, efficient and flexible tablet-manufacturing technology that, in combination with PAT, allows easy adoption of a QbD approach, ensuring excellent operation performance and avoiding waste during startup and shutdown.
Pharma companies are working hard to improve diversity in both drug-related trials and in the ways they do business. To that end, in 2022 Intellus formed its Diversity, Equity, and Inclusion Task Force to rally multiple parties including pharma and biotech firms, insights providers, and panel recruitment experts to close this gap.
Through our work with commercial and brand teams across a range of large and mid-sized pharma companies , we’ve been able to identify three areas where the industry can achieve fast, tangible impact using advanced patient journey analytics to fully crystallize the elusive patient journey.
We have reported several times on supply chain resilience since the start of the COVID-19 pandemic, 1-3 as the world experienced unprecedented lockdowns and supply disruptions, with interruptions to manufacturing as well as both air transportation and shipping routes.
In the September 2021 issue of PM360 , Jean Drouin, MD, CEO, Clarify Health, shared innovative ways that pharma’s addressing health inequities with SDoH insights.
Soulsby and Brooks explain what the new certification means for antibiotic manufacturers and the wider pharma industry, and its anticipated benefit for supply chain sustainability. What will be the biggest impact of the certification on the pharma supply chain?
He outlines five key challenges in the CGT supply chain including: Regulatory compliance: The supply chain must comply with the complex regulations governing the transport of CGT materials, including GDP and IATA requirements. This also includes the completion of critical shipping paperwork. Internet] GlobalData. cited 2024May].
Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. This typically adds 3x more costs with oversight, storage, and transportation than traditional therapies.
Enosis Therapeutics, makers of AnchoringVR, uses virtual reality to transport the user out of a typical, clinical treatment environment into an alternate reality by replacing familiar settings with wondrous objects and symbols. Most pharma brands today are already exploring how to lessen their carbon footprint.
Roche Pharma Partnering global head James Sabry said: “We have been impressed by Jnana’s team and their RAPID drug discovery platform as part of our first collaboration that focused on SLC metabolite transporters. “As Additionally, Roche will oversee the development and marketing of any products resulting from the partnership.
The industry has been limited in its ability to implement creative solutions to engage and motivate patients because the FDA has strict guidelines for what pharma companies can communicate with patients. Yet, pharma companies spend more than $5 billion on patient support programs every year, and only 3% of patients are using them.
To find out, PM360 asked experts within patient groups, pharma companies, and other industry partners: What are the keys to building trusting and mutually beneficial partnerships? do rare disease patients and advocacy groups most value or need from pharma? So, what are the keys to working with these groups?
Compliance with good distribution practice (GDP) ensures that medicine quality and integrity are maintained throughout the supply chain, while compliance with good manufacturing practice (GMP) ensures efficient distribution, storage, packaging, transportation, documentation, labelling, and record-keeping practices.
Amgen buying Horizon Therapeutics and Ipsen ’s acquisition of Albireo Pharma show an increased appetite for investment in therapies for rare diseases. The mutation leads to disordered thyroid hormone transport, which causes patients to experience intellectual and motor disabilities. This was not always the case. “Up
By fostering cross-stakeholder coordination and support across pharma brands, HCPs, pharmacies, and insurance companies, we can pave the way for better solutions that enhance adherence and, ultimately, improve patient outcomes. Through united efforts, we can mitigate this significant challenge and improve patient care.
After more than two years of pandemic restrictions, many Pharma leaders are itching to meet with their key opinion leaders (KOLs) face-to-face again, believing that’s what most KOLs want. Advisor preference! Let’s jump right in, shall we? It may come as a surprise that this is not always the case.
From transport and handling of raw bulk materials, monitoring milling and weighing, to transporting downstream for any supplementary processes that may be required such as additional milling or powder handling. Pharma products cannot be modified to adapt to a standardised equipment setup.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content